Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMHVWIK)

Drug Name
Cefepime Drug Info
Synonyms
Axepim; CFPM; Cefepima; Cefepimum; Cepimax; Cepimex; Maxcef; Maxipime; Cefepima [Spanish]; Cefepimum [Latin]; BMY 28142; Axepim (TN); BMY-28142; Cefepime [USAN:INN]; Cepimax (TN); Cepimex (TN); Maxcef (TN); Maxipime (TN); Cefepime (USAN/INN); (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
Therapeutic ClassAntibiotics
Cross-matching ID
PubChem CID
5479537
ChEBI ID
CHEMBL186
CAS Number
CAS 88040-23-7
TTD Drug ID
D0A1CB
VARIDT Drug ID
DR00585

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome 2.57 0.00e+0 113/158 (71.52%) MRPS2;MRPL9;MRPL13;...
Oxidative phosphorylation 2.13 0.00e+0 93/133 (69.92%) COX7A1;NDUFS6;COX7A2;...
DNA replication 2.03 0.00e+0 34/36 (94.44%) POLE2;RPA3;POLD2;...
Ribosome biogenesis in eukaryotes 1.93 1.36e-3 52/108 (48.15%) NVL;RAN;POP4;...
Base excision repair 1.91 1.09e-3 29/33 (87.88%) POLE2;POLD2;APEX1;...
Proteasome 1.84 6.36e-3 44/46 (95.65%) PSMA2;PSMA6;PSMB5;...
RNA polymerase 1.83 6.23e-3 23/31 (74.19%) POLR3K;POLR1D;POLR3B;...
Thermogenesis 1.80 1.09e-2 173/232 (74.57%) COX7A1;NDUFS6;COA3;...
Fanconi anemia pathway 1.79 1.09e-2 36/54 (66.67%) RPA3;CENPX;FANCG;...
Steroid hormone biosynthesis 1.72 2.07e-2 43/61 (70.49%) AKR1C2;UGT2B4;AKR1C1;...
Nucleotide excision repair 1.71 1.98e-2 40/47 (85.11%) POLE2;RPA3;RBX1;...
Huntington disease 1.65 3.59e-2 233/306 (76.14%) COX7A1;PSMA2;PSMA6;...
Legionellosis 1.63 3.94e-2 51/57 (89.47%) CXCL2;EEF1A2;PYCARD;...
Diabetic cardiomyopathy 1.62 3.78e-2 162/203 (79.8%) COX7A1;MPC1;NDUFS6;...
Hepatitis C -1.63 4.95e-2 139/157 (88.54%) CLDN6;CLDN18;PPP2R2A;...
Glycosaminoglycan degradation -1.63 4.89e-2 19/19 (100%) NAGLU;GUSB;GLB1;...
Long-term depression -1.65 4.79e-2 55/60 (91.67%) ITPR1;MAPK3;GNAZ;...
Human papillomavirus infection -1.65 4.60e-2 284/331 (85.8%) ATP6V0E2;CCND1;PIK3CA;...
Small cell lung cancer -1.65 4.67e-2 90/92 (97.83%) CCND1;PIK3CA;BCL2;...
Epstein-Barr virus infection -1.66 4.75e-2 189/202 (93.56%) CXCL10;TAPBP;MAPK11;...
Th17 cell differentiation -1.66 4.95e-2 95/107 (88.79%) RXRB;MAPK11;IL27RA;...
Regulation of lipolysis in adipocytes -1.67 4.90e-2 52/55 (94.55%) NPR1;PIK3R1;FABP4;...
Colorectal cancer -1.70 3.27e-2 84/86 (97.67%) CCND1;PIK3CA;BCL2;...
Gastric cancer -1.73 2.78e-2 122/149 (81.88%) CCND1;PIK3CA;BCL2;...
Endometrial cancer -1.73 2.70e-2 56/58 (96.55%) CCND1;PIK3CA;GSK3B;...
Aldosterone-regulated sodium reabsorption -1.73 2.86e-2 34/37 (91.89%) PRKCA;NR3C2;KCNJ1;...
Staphylococcus aureus infection -1.74 2.52e-2 72/95 (75.79%) SELP;HLA-DPA1;HLA-DRB1;...
MicroRNAs in cancer -1.74 2.69e-2 146/310 (47.1%) CCND2;RECK;BAK1;...
Estrogen signaling pathway -1.75 2.28e-2 119/137 (86.86%) KRT20;PRKCD;NCOA3;...
Antigen processing and presentation -1.77 2.35e-2 60/78 (76.92%) KIR3DL1;KIR2DL3;HSPA6;...
Adherens junction -1.77 2.32e-2 63/71 (88.73%) TCF7L2;YES1;TGFBR2;...
Graft-versus-host disease -1.78 2.15e-2 32/42 (76.19%) GZMB;IL1B;KIR3DL1;...
Mucin type O-glycan biosynthesis -1.80 1.81e-2 20/36 (55.56%) GALNT10;B4GALT5;GALNT2;...
Prostate cancer -1.81 1.70e-2 93/97 (95.88%) NFKBIA;NKX3-1;ETV5;...
Mineral absorption -1.84 1.39e-2 48/60 (80%) SLC11A2;SLC34A1;SLC39A4;...
Cocaine addiction -1.84 1.59e-2 42/49 (85.71%) CREB3L2;PRKACB;JUN;...
Parathyroid hormone synthesis, secretion and action -1.85 1.62e-2 98/106 (92.45%) KL;SLC34A1;ADCY6;...
Non-small cell lung cancer -1.90 1.67e-2 70/72 (97.22%) ALK;CCND1;PIK3CA;...
Pancreatic cancer -1.93 1.39e-2 75/76 (98.68%) MAPK8;ARHGEF6;BAK1;...
Type I diabetes mellitus -1.94 1.39e-2 38/43 (88.37%) GAD2;HLA-C;HLA-G;...
Lysosome -1.97 2.08e-2 115/128 (89.84%) GALNS;ATP6V0A1;SORT1;...
Other glycan degradation -2.03 0.00e+0 13/18 (72.22%) GLB1;MAN2B1;HEXA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H